|
JP4834553B2
(ja)
*
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
|
US9006240B2
(en)
*
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
|
US20090053236A1
(en)
|
2005-11-07 |
2009-02-26 |
Eisai R & D Management Co., Ltd. |
USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
|
|
RU2448708C3
(ru)
*
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
|
EP2119707B1
(en)
*
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
WO2009060945A1
(ja)
*
|
2007-11-09 |
2009-05-14 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
KR20140038382A
(ko)
|
2011-03-10 |
2014-03-28 |
프로벡투스 파마슈티컬스 인코포레이티드 |
암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제
|
|
JP6021805B2
(ja)
*
|
2011-04-18 |
2016-11-09 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
CN104704002B
(zh)
*
|
2012-08-30 |
2022-05-10 |
安姆根有限公司 |
使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
|
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
|
TWI726291B
(zh)
*
|
2013-01-07 |
2021-05-01 |
英屬維爾京群島商遠東超級實驗室有限公司 |
通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
|
|
US12421502B2
(en)
|
2013-04-18 |
2025-09-23 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
FI3461491T3
(fi)
*
|
2013-04-18 |
2025-02-20 |
Tilt Biotherapeutics Oy |
Tehostettu adoptiivinen soluterapia
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
PL3134123T3
(pl)
*
|
2014-02-21 |
2021-07-12 |
Nektar Therapeutics (India) Pvt. Ltd. |
Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
|
|
AU2015218633A1
(en)
*
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
|
US20170088626A1
(en)
|
2014-03-05 |
2017-03-30 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
CA2949121A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
SMT202200367T1
(it)
|
2014-08-28 |
2022-11-18 |
Eisai R&D Man Co Ltd |
Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
|
|
WO2016106146A1
(en)
|
2014-12-23 |
2016-06-30 |
The Regents Of The University Of California |
Methods for immunomodulation of cancer and infectious disease therapy
|
|
CN104459129A
(zh)
*
|
2015-01-05 |
2015-03-25 |
复旦大学附属华山医院 |
一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
|
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
DK3283107T3
(da)
|
2015-04-17 |
2020-08-31 |
Bristol Myers Squibb Co |
Sammensætninger omfattende en kombination af ipilimumab og nivolumab
|
|
EP3288982A1
(en)
|
2015-04-28 |
2018-03-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
|
AU2016309356B2
(en)
|
2015-08-20 |
2021-06-24 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
AU2015414272B2
(en)
|
2015-11-11 |
2021-04-22 |
Agalimmune Limited |
Glycolipid compounds and their uses in the treatment of tumours
|
|
US11072657B2
(en)
|
2015-11-18 |
2021-07-27 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
|
|
US10130658B2
(en)
*
|
2015-12-18 |
2018-11-20 |
Provectus Pharmatech, Inc. |
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
|
|
HRP20220525T1
(hr)
|
2015-12-23 |
2022-05-27 |
Modernatx, Inc. |
Postupci uporabe polinukleotida koji kodiraju ligand ox40
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
WO2017180841A1
(en)
*
|
2016-04-13 |
2017-10-19 |
The Regents Of The University Of California |
Treatment of cerebral cavernous malformations
|
|
PT3458474T
(pt)
|
2016-05-18 |
2022-11-08 |
Modernatx Inc |
Combinações de arnm que codificam polipéptidos de modulação imunitária e as suas utilizações
|
|
CN109195621A
(zh)
|
2016-05-18 |
2019-01-11 |
莫得纳特斯公司 |
编码白细胞介素12(il12)的多核苷酸及其用途
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
JP7169195B2
(ja)
|
2016-05-20 |
2022-11-10 |
バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド |
癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
HRP20230864T1
(hr)
|
2016-06-02 |
2023-11-10 |
Bristol-Myers Squibb Company |
Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
|
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
|
WO2017210637A1
(en)
|
2016-06-03 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
|
|
CN110099925A
(zh)
|
2016-10-28 |
2019-08-06 |
百时美施贵宝公司 |
使用抗pd-1抗体治疗尿道上皮癌的方法
|
|
US11040027B2
(en)
|
2017-01-17 |
2021-06-22 |
Heparegenix Gmbh |
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
ES2971448T3
(es)
|
2017-02-08 |
2024-06-05 |
Eisai R&D Man Co Ltd |
Composición farmacéutica para el tratamiento de tumores
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
CN110678750A
(zh)
|
2017-04-28 |
2020-01-10 |
美国默沙东药厂 |
用于癌症治疗的生物标志物
|
|
CN121159691A
(zh)
|
2017-05-12 |
2025-12-19 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
CA3061888A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
|
GB201710097D0
(en)
*
|
2017-06-23 |
2017-08-09 |
Univ Ulster |
A sensitizer - peptide conjugate
|
|
US11351163B2
(en)
|
2017-09-29 |
2022-06-07 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EA202090817A1
(ru)
|
2017-10-13 |
2020-09-08 |
Харпун Терапьютикс, Инк. |
Триспецифические белки и способы их применения
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
US11426379B2
(en)
|
2017-11-29 |
2022-08-30 |
Provectus Pharmatech, Inc. |
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
|
|
WO2019143607A1
(en)
|
2018-01-16 |
2019-07-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
EP3743076A1
(en)
|
2018-01-22 |
2020-12-02 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
US20210032344A1
(en)
|
2018-03-30 |
2021-02-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN112996502B
(zh)
*
|
2018-05-16 |
2023-10-31 |
普罗维克图斯药品技术公司 |
卤代呫吨针对难治性小儿实体瘤的体外和异种移植抗肿瘤活性
|
|
MX2020012534A
(es)
|
2018-05-27 |
2021-04-28 |
Biolinerx Ltd |
Agi-134 combinado con un inhibidor de punto de control para el tratamiento de tumores solidos.
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
CN112912403A
(zh)
|
2018-10-23 |
2021-06-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
|
EP3886842A1
(en)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Combination treatment of hiv infections
|
|
GB201819853D0
(en)
*
|
2018-12-05 |
2019-01-23 |
Innovation Ulster Ltd |
Therapy
|
|
MX2021007860A
(es)
|
2018-12-28 |
2021-10-26 |
Transgene |
Poxvirux deficiente en m2.
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
JP2022549273A
(ja)
|
2019-09-22 |
2022-11-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
CN115942973A
(zh)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
用于黑色素瘤的lag-3拮抗剂疗法
|
|
JP7528242B2
(ja)
*
|
2019-11-19 |
2024-08-05 |
プロヴェクタス ファーマテック，インク． |
血液がんを治療するための組成物および方法
|
|
US11419844B2
(en)
|
2019-11-19 |
2022-08-23 |
Provectus Pharmatech, Inc. |
Halogenated xanthene composition and method for treating hematologic cancers
|
|
US12064507B2
(en)
|
2019-11-19 |
2024-08-20 |
Provectus Pharmatech, Inc. |
Composition and method for oral treatment of leukemia
|
|
US20230089255A1
(en)
|
2019-12-19 |
2023-03-23 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｌ－１０およびその使用
|
|
JP7512409B6
(ja)
*
|
2020-03-26 |
2024-07-23 |
プロヴェクタス ファーマテック，インク． |
腫瘍学及びウイルス学におけるハロゲン化キサンテンの新規の使用
|
|
US11938182B2
(en)
*
|
2020-03-26 |
2024-03-26 |
Provectus Pharmatech, Inc. |
Halogenated xanthenes as vaccine adjuvants
|
|
EP4157319A1
(en)
|
2020-05-28 |
2023-04-05 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
BR112023003553A2
(pt)
|
2020-08-31 |
2023-04-04 |
Bristol Myers Squibb Co |
Assinatura de localização celular e imunoterapia
|
|
JP2023548051A
(ja)
|
2020-10-23 |
2023-11-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
肺がんのためのｌａｇ－３アンタゴニスト療法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
EP4566674A3
(en)
|
2020-12-28 |
2025-08-06 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
KR20240099362A
(ko)
|
2021-10-29 |
2024-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
혈액암에 대한 lag-3 길항제 요법
|
|
JP2025503962A
(ja)
|
2022-01-26 |
2025-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞がんのための併用療法
|
|
EP4482947A1
(en)
|
2022-02-24 |
2025-01-01 |
Amazentis SA |
Uses of urolithins
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
AU2023230110A1
(en)
|
2022-03-08 |
2024-10-24 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
US20250332252A1
(en)
|
2022-06-02 |
2025-10-30 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2025523573A
(ja)
|
2022-07-01 |
2025-07-23 |
トランジェーヌ |
サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|